TANEN DAVID M 4
4 · Kronos Bio, Inc. · Filed Oct 16, 2020
Insider Transaction Report
Form 4
Kronos Bio, Inc.KRON
TANEN DAVID M
Director
Transactions
- Conversion
Common Stock
2020-10-14+68,831→ 434,111 total(indirect: See footnote) - Conversion
Series Seed Preferred Stock
2020-10-14−219,482→ 0 total→ Common Stock (231,553 underlying) - Conversion
Common Stock
2020-10-14+231,553→ 363,428 total - Conversion
Series A Preferred Stock
2020-10-14−65,243→ 0 total(indirect: See footnote)→ Common Stock (68,831 underlying) - Conversion
Common Stock
2020-10-14+233,405→ 365,280 total(indirect: See footnote) - Conversion
Series Seed Preferred Stock
2020-10-14−221,237→ 0 total(indirect: See footnote)→ Common Stock (233,405 underlying) - Conversion
Convertible Promissory Note
2020-10-14→ 0 total(indirect: See footnote)Exercise: $16.15Exp: 2022-02-20→ Common Stock (37,119 underlying) - Conversion
Common Stock
2020-10-14$16.15/sh+37,119$599,472→ 471,230 total(indirect: See footnote)
Holdings
- 26,375(indirect: By Son)
Common Stock
- 26,375(indirect: By Daughter)
Common Stock
- 26,375(indirect: By Son)
Common Stock
Footnotes (3)
- [F1]Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
- [F2]By the David Tanen Revocable Grantor Trust.
- [F3]The convertible promissory note automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering.